Andrew Slavitt
About Andrew Slavitt
Andrew Slavitt, age 58, is an independent director of NeueHealth, Inc. (NEUE). He has served since August 2021 (and previously from April 2018–January 2021 when he left to serve as President Biden’s White House Senior Advisor for the COVID-19 response). He is the founder and General Partner of Town Hall Ventures, and formerly served as Acting Administrator of the Centers for Medicare & Medicaid Services (CMS) and as a senior Optum/UnitedHealth Group executive, bringing deep healthcare policy and payer/operator expertise to the board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Centers for Medicare & Medicaid Services (CMS) | Acting Administrator | 2015–2017 | Led federal healthcare programs; regulatory and policy oversight |
| Optum (UnitedHealth Group) | Group EVP | 2012–2014 | Senior leadership across health services platform |
| OptumInsight (UnitedHealth Group) | CEO (formerly Ingenix) | 2006–2011 | Grew analytics/IT services; payer/provider data/operations expertise |
| The White House | Senior Advisor to the President (COVID-19 response) | 2021 | Public health crisis leadership |
External Roles
| Organization | Role | Tenure/Status |
|---|---|---|
| Town Hall Ventures | Founder & General Partner | Since 2018 (current) |
| Cityblock Health, Inc. | Director | Current (private company) |
| Equality Health, LLC | Director | Current (private company) |
| Bipartisan Policy Center | Co-chair, Future of Healthcare Initiative | Current |
| Capella Education Company (Nasdaq: CPLA, former) | Director | Prior public company role |
Board Governance
| Governance Item | Detail |
|---|---|
| Independence | Independent (Board determined all directors except G. Mike Mikan and Robert J. Sheehy are independent) |
| Committee memberships (2024) | Not listed as a member of Audit, Compensation & Human Capital, or Nominating & Corporate Governance Committees |
| Attendance | In 2024, each director attended at least 75% of Board/committee meetings during their tenure; Board held 8 meetings |
| Committee meeting frequency (2024) | Audit 4; Compensation & Human Capital 3; Nominating & Corporate Governance 0 |
| Board leadership | Chair: Robert J. Sheehy; Lead Director: Manuel Kadre |
Fixed Compensation
| Component | Policy / 2024 Actual | Amount / Detail |
|---|---|---|
| Annual cash retainer (policy) | Non-employee director retainer | $80,000 |
| Committee chair retainers (policy) | Audit $25,000; Compensation $20,000; Nominating $15,000; other committee members $10,000 | Amounts pro rata if partial year |
| 2024 cash actually paid to A. Slavitt | Fees earned/paid in cash (includes committee/member fees as applicable) | $171,000 |
| 2024 equity grant (policy adjustment) | Due to limited shares, directors approved 10,500 RSUs and a supplemental $91,000 retainer payable on first anniversary; paid in cash in April 2025 | RSUs granted; supplemental paid in cash April 2025 |
| Director compensation mix (2024 actual for A. Slavitt) | Cash vs Equity | Cash $171,000; RSU fair value $63,735; Total $234,735 |
Performance Compensation
| Award Type | Grant Date | Shares/Units | Vesting | Grant Date Fair Value |
|---|---|---|---|---|
| RSUs (Director annual grant) | May 13, 2024 | 10,500 | 100% vests on first anniversary (time-based) | $63,735 |
- No performance-conditioned metrics are disclosed for director equity; grants are time-based RSUs (not PSU/TSR-based) .
- As of 12/31/2024, Andrew Slavitt also held 3,505 options; strike/expiry not disclosed in the director table .
Other Directorships & Interlocks
| Topic | Detail |
|---|---|
| Current public company boards | None disclosed for Mr. Slavitt (current roles are at private companies) |
| Town Hall Ventures relationship | Town Hall Ventures (founded/managed by Mr. Slavitt) is party to the Company’s registration rights agreement; Town Hall Ventures entities beneficially own common and Series B preferred of NEUE |
| Board-level venture ties | NEA is the majority holder and credit provider; the board includes NEA-affiliated directors (e.g., Mohamad Makhzoumi; Jeffrey Immelt is an NEA venture partner) and the company has a pending take-private merger with an NEA affiliate |
Expertise & Qualifications
- Healthcare policy and regulatory leadership from CMS Acting Administrator role; crisis management from White House COVID-19 advisory role .
- Payer/operator experience as CEO of OptumInsight and Group EVP at Optum/UnitedHealth Group .
- Venture investing/operator enablement via Town Hall Ventures with focus on vulnerable communities .
- Not designated as an “audit committee financial expert” (Audit Committee experts are Adkins, Kadre, Gooden) .
Equity Ownership
| Category | Shares / Units | Notes |
|---|---|---|
| Direct common stock | 8,029 | Directly held |
| Options exercisable (within 60 days of 4/8/2025) | 3,505 | Director options |
| RSUs vesting (within 60 days of 4/8/2025) | 10,500 | 2024 director grant vesting schedule |
| Slavitt Holdings LLC | 5,625 | Indirect ownership (Mr. Slavitt sole manager) |
| Town Hall Ventures II LP | 30,687 | As managing member of its GP |
| Town Hall Ventures LP | 52,969 | As managing member of its GP |
| Series B Preferred (THV II) → common | 52,356 | Shares issuable upon conversion of 4,200 Series B preferred |
| Total beneficial ownership | 163,671 | 1.8% of outstanding shares |
| Hedging/Pledging | None pledged in 2024; hedging prohibited without pre-clearance | Company-wide policy; no pledges by directors in 2024 |
| Section 16 filings | No late Section 16 reports in 2024 | Company statement for directors/officers |
Governance Assessment
-
Strengths
- Independence affirmed; attendance met/exceeded 75% threshold; board met 8 times in 2024 .
- Strong healthcare policy and payer/operator background improves oversight on value-based care strategy and regulatory risk .
- Alignment mechanisms: director stock ownership guideline equal to 3x annual cash retainer; company-wide clawback, anti-hedging/pledging policies bolster investor protections .
-
Watch items / potential conflicts
- Related-party exposure: Town Hall Ventures is party to the registration rights agreement and holds common/convertible preferred—Mr. Slavitt serves as GP, creating potential perceived conflicts on capital markets/liquidity events; board’s related-person transaction policy requires recusal/approval for such matters .
- Concentrated sponsor influence: NEA controls a majority stake, provided credit with warrants, and is the buyer in the pending take-private—Board includes NEA-affiliated members, heightening the need for rigor in special committee processes; while not attributed to Mr. Slavitt, it shapes overall governance dynamics .
- Compensation structure (2024): due to limited share availability, directors received a $91,000 supplemental retainer later paid in cash (April 2025), tilting mix toward cash vs equity for that cycle; this is a one-time adjustment but modestly reduces equity alignment for 2024 .
-
Overall
- No red flags on attendance, independence, hedging/pledging, or Section 16 compliance specific to Mr. Slavitt. Primary sensitivity relates to his fund’s (Town Hall Ventures) shareholder status and registration rights; ensuring strict adherence to related-party policies and appropriate recusals remains important for investor confidence .